CAPO - Program

IPOS 2022: WORLD CONGRESS REIMAGINING PSYCHOSOCIAL ONCOLOGY: EMBRACING VOICES FROM AROUND THE WORLD

TORONTO, CANADA • AUGUST 29 - SEPTEMBER 1, 2022

PROGRAM

IPOS 2022 Speakers

PROGRAM

DATE/TIME (Eastern Daylight Time)	SESSION
Monday August 29	Pre-Congress Academy Workshops
0830-1200	Full day: Distress screening with adolescents and young adults with cancer: Why, how, and what to do next A Framework and Staffing Formula Ratio for Hiring Health Care Professionals in Psychosocial Oncology Programming Half day: Integrating Psychosocial Care Across the Cancer Control Continuum: What Does it Take? Integrative Model of Cancer Experience in Children and Teenagers through the use of Art The Clinical Challenge of Uncertainty – Using ACT based approaches to support our patients Virtual: Sexual and Gender Diversity in Cancer Care (SGDc): Developing Communication Skills to Foster Inclusive Cancer Care
1200-1300	Break
1300-1630	Full day: Distress screening with adolescents and young adults with cancer: Why, how, and what to do next A Framework and Staffing Formula Ratio for Hiring Health Care Professionals in Psychosocial Oncology Programming Half day: Mindfulness as a coping strategy for cancer survivors As the End Nears – Working with AYAs with Advanced Disease Advancing Evidence-based Integrative Oncology in the Global Cancer Care Community An Art Exhibit: Illuminating our Grounded Theory about Patients’ Experiences with a Mindfulness-based Expressive Arts Group
1700-1900	Welcome Opening Reception
Tuesday August 30	Congress Day 1
0800-0845	Opening Comments Featuring an address by Bill Brummal
0845-1015	Concurrent Sessions
1015-1030	Break and poster session
1030-1130	Plenary 1 Kim Thiboldeaux “Raising Our Voices to Reduce Cancer Disparities: Bringing Cancer Care to American Indian Tribal Lands”
1130-1300	Concurrent Sessions: Symposia Invited symposium: “Global Psycho-Oncology: Ensuring Equitable and Culturally Relevant Access in Low Middle Income Countries” Melissa Henry (Moderator) Christian Ntizimira Santosh Chaturvedi Roxana Aguilar Velarde
1300-1400	Lunch and poster Session Patient Attendee Welcome event
1400-1500	Plenary 2 Lonneke van der Poll-Franse “Survivorship care in the new landscape of personalized medicine”
1500-1515	Break and poster session
1515-1645	Concurrent Sessions
1645-1800	Concurrent Sessions
Wednesday August 31	Congress Day 2
0830-0945	Concurrent Sessions
0945-1045	Plenary 3 – President’s Plenary
1045-1115	Break and poster session
1115-1245	Concurrent Sessions Invited symposium: “Moving towards culturally sensitive care for fear of cancer recurrence: A global perspective” Sophie Lebel (Moderator) Allan “Ben” Smith Isabel Centeno Yuan Yang
1245-1345	Lunch and Poster Session
	IPOS AGM
1345-1445	Plenary 4 Anthony Bossis “Use of Psilocybin for the Treatment of Psychosocial Distress in Palliative Care and at the End-of-Life”
1445-1515	Break and poster session
1515-1645	Concurrent Sessions
1700	Congress Social (TBC)
Thursday September 1	Congress Day 3
0830-1000	Concurrent Sessions
1000-1100	Plenary 5 Nicole Rankin “Embracing health equity: opportunities to transform research translation in psycho-oncology”
1100-1230	Concurrent Sessions
1230-1330	Lunch and Poster Session
1330-1445	Plenary 6 Roger Levesque "Taming Uncertainty: Facing Cancer in the COVID Era"
1445-1615	Concurrent Sessions
1615-1700	Closing Ceremonies – IPOS/CAPO Awards

KEYNOTE SPEAKERS

ANTHONY P. BOSSIS Ph.D

Use of Psilocybin for the Treatment of Psychosocial Distress in Palliative Care and at the End-of-Life

Anthony P. Bossis, Ph.D. is a clinical psychologist and clinical assistant professor of psychiatry at NYU Grossman School of Medicine and NYU Center for Psychedelic Medicine conducting FDA-approved research with the psychedelic compound psilocybin since 2006. Dr. Bossis was director of palliative care research and co-principal investigator on the landmark 2016 clinical trial demonstrating a significant reduction in emotional distress from a single psilocybin session in persons with cancer, specifically, a rapid decrease in depression, anxiety, hopelessness, and demoralization along with improvements in spiritual well-being and quality of life. He is study director and lead therapist on an FDA-approved clinical trial investigating a psilocybin-generated mystical experience upon religious leaders. Dr. Bossis is a training supervisor of psychotherapy at NYU-Bellevue Hospital and co-founder of the Bellevue Hospital Palliative Care Service. He is on the editorial board of the Journal of Humanistic Psychology and a guest editor (with Charles Grob, M.D.) for the journal’s Special Series on Psychedelics. His primary psychedelic research interests are the treatment of end-of-life existential distress and the study of consciousness, meaning, and spirituality. He maintains a private psychotherapy and consulting practice in NYC.

ASSOCIATE PROFESSOR NICOLE RANKIN

Embracing health equity: opportunities to transform research translation in psycho-oncology

Associate Professor Nicole Rankin is an implementation scientist in the Sydney School of Public Health, Faculty of Medicine and Health, University of Sydney, Australia. Nicole is Director of the Implementation Science Program at Sydney Health Partners, which is a collaboration between the University of Sydney and four Local Health Districts, whose goal is to demonstrate how evidence-based interventions can be successfully implemented and scaled-up in diverse and complex health systems.

A/Prof Rankin’s research focuses on the science of research translation, including how evidence can be more rapidly translated into clinical practice, with a significant focus on lung cancer. Her research portfolio extends from lung cancer screening, early detection, and management through to multidisciplinary care, palliative care and survivorship. Her interests include psychosocial care and how health services can better meet the needs of people diagnosed with cancer and other chronic conditions. Her expertise is applied across a portfolio of research projects, in leading capacity building initiatives such as masterclasses, workshops and conferences, as well as mentoring clinician-researchers and doctoral candidates to develop their careers in research translation.

KIM THIBOLDEAUX

Raising Our Voices to Reduce Cancer Disparities: Bringing Cancer Care to American Indian Tribal Lands

Kim Thiboldeaux is a nonprofit executive, thought leader, and author who has made her mark on the global stage by ensuring that the patient’s voice is at the center of every conversation about cancer. Thiboldeaux served as CEO of the Cancer Support Community (CSC) for 20 years, from 2000-2020, leading a global nonprofit network that operates at 175 locations, including CSC and Gilda's Club centers, and in multiple hospitals and cancer clinics. Thiboldeaux’s service includes appointments to the nation’s premier panels on cancer. In 2019, Dr. Francis S. Collins, Director of the National Institutes of Health, appointed Thiboldeaux to the Novel and Exceptional Technology and Research Advisory Committee. In 2017, she was appointed to serve on the Biden Cancer Initiative’s Board of Directors.

In serving as a patient advocate on these high-profile boards and panels, Thiboldeaux has brought attention to inequities in our health care system. In 2019, she joined Navajo Nation President Jonathan Nez, Dr. Jill Biden, and leaders of the Tuba City Regional Health Care Corporation in Arizona to mark the opening of the first-ever full-time cancer care and support center on native land in the US. After securing a generous gift from the Barbara Bradley Baekgaard Family Foundation, Thiboldeaux helped convene key Navajo Nation leaders, private sector supporters, and other officials to establish this culturally-adapted program located in an area larger than the state of West Virginia. In 2020, Stand Up To Cancer appointed Thiboldeaux to its Equity Breakthrough Research Review Team, focusing on cancers affecting underrepresented populations. In 2019, the International Psychosocial Oncology Society presented Thiboldeaux with the President’s Community Award for Distinguished Contributions at its global Congress in Canada.

Thiboldeaux’s insights are highly sought after, with interviews including the Wall Street Journal, The Washington Post, PBS, Philadelphia Inquirer, WebMD, and speaking engagements, including a TEDx Talk and White House convenings. She is the author of the 2021 full-length book Your Cancer Map-Navigating Life With Resilience, Foreword by Dr. Jill Biden. Her writing is featured on Medium and also in the Huffington Post. Thiboldeaux graduated from American University with a bachelor’s degree in communications and a minor in Spanish. While at American, Thiboldeaux studied abroad in London and Buenos Aires, experiences that spurred her lifelong zest for travel. She has visited all seven continents, all 50 states, and 50-plus countries, and has no intention of slowing down her exploration of new countries and cultures.

ROGER LEVESQUE

Taming Uncertainty: Facing Cancer in the COVID Era

Roger Levesque speaks to the steep ups and downs of being diagnosed with Stage IV cancer nearly two years ago, his treatments and experience in the medical system during the pandemic, and his insights as a standardized patient helping to train medical personnel.

As an arts journalist for over 35 years and radio broadcaster for over 25 years, Levesque has devoted much of his career to writing about musicians and movies, and programming jazz and global music for several public radio stations in Edmonton, Alberta.

Two personal stories about his diagnosis and treatments published in The Edmonton Journal and The National Post across Canada made him a finalist in the 2020 National Newspaper Awards.

LONNEKE VAN DE POLL-FRANSE

Survivorship care in the new landscape of personalized medicine

Lonneke van de Poll-Franse is Professor of Cancer Epidemiology and Survivorship at the Netherlands Cancer Institute (NCI)/ Netherlands Comprehensive Cancer Organisation and Tilburg University.

Her research focuses on identifying and understanding the physical and psychological consequences of cancer and treatment. In 2009 she set up the Patient Reported Outcomes Following Initial treatment and Long-term Evaluation of Survivorship (PROFILES) registry, which combines population data from the Netherlands Cancer Registry with patient-reported outcomes (www.profilesregistry.nl) as well as information on nutrition and physical activity measured with apps and wearables.

At the NCI - Center for Quality of Life, Professor van de Poll leads the survivorship research program. A key pillar of this program is the collection of PROMs and provision of personalized care and support in daily clinical care. Her observational research informs the development of evidence-based interventions to optimize care and outcomes of survivors; she is PI of several multicenter RCTs on the effectiveness of new models of survivorship care.

Van de Poll-Franse is an active member of the EORTC Quality of Life group, sits on the scientific advisory boards of several European cancer institutes, and participates in EU research consortia on better care and quality of life for cancer survivors.

INVITED SYMPOSIA

Moving towards culturally sensitive care for fear of cancer recurrence: A global perspective

Professor Sophie Lebel is a professor at the University of Ottawa and a clinical psychologist with a focus on cancer survivorship and psychosocial interventions. She has contributed to the definition and measurement of fear of cancer recurrence and clinical fear of recurrence, co-authored several systematic reviews on this fear, and developed and validated a model of fear of cancer recurrence. She co-developed FORT, a cognitive existential group intervention for survivors that has been tested through clinical trials. She is currently chairing the writing of clinical practice guidelines for the management of fear of cancer recurrence in Ontario, Canada. She is supervising Ph.D. candidates in her lab who are working on the adaptation of FORT for family caregivers of cancer patients, developing new measures of clinical fear of recurrence, and studying uncertainty and fear of progression in advanced cancer patients who are receiving targeted therapy and immunotherapy. In 2015, she held a colloquium on fear of cancer recurrence at the University of Ottawa that led to the creation of FORwards, the IPOS special interest group on Fear of Cancer recurrence, which she chaired from 2017-2019.

Introducing Fear of cancer Recurrence (FCR) care in a Mexican breast cancer women group

Isabel Centeno is a psychooncologist specialized in chronic advanced diseases. She is a member of the muldisciplinary Breast Cancer Center team at Zambrano Hellion Hospital and a Medicine school´s professor at Tecnológico de Monterrey. She has particular interest in end of life care, fear of cancer recurrence and compassion in Health settings. She is founder of Travesías de Tinta, a creative writing mental health foundation.

Improving consistency and equity of care for fear of cancer recurrence through an evidence-based, culturally sensitive and implementation-ready clinical pathway

Dr. Ben Smith is a Cancer Institute NSW Career Development Fellow at the Ingham Institute and University of New South Wales, Medicine & Health. Ben’s research aims to ensure equitable access to high quality evidence-based survivorship care for all people living with cancer. He has a particular interest in fear of cancer recurrence, digital health, and implementation science.

Fear of cancer recurrence in China, prevalence, risk factors, relationships with other psychiatric comorbidities, and clinical management

Yuan Yang, PhD, is a clinical psychotherapist in Guangdong Mental Health Center, Guangdong Provincial People’s Hospital, China. She is also a member of the Chinese Psycho-Oncology Society (CPOS). Dr. Yang obtained her bachelor degree in Southern Medical University, China, and obtained her Master degree in the University of Edinburgh, UK. She then worked as a research assistant at the University of St Andrews (School of Medicine, with Prof. Gerry Humphris) and Western General Hospital (Edinburgh Cancer Center). Then she returned to China, worked as a clinical psychotherapist in Southern Medical University Nanfang Hospital, and obtained her PhD in the University of Macau, Macau SAR. Dr. Yang’s research mainly focuses on Psycho-oncology, Mood Disorders, Psychiatric Epidemiology, and Counselling and Psychotherapy. She has authored or co-authored over 50 papers in international journals, including Lancet Psychiatry, Lancet Regional Health-Western Pacific, and Lancet Public Health.

Global Psycho-Oncology: Ensuring Equitable and Culturally Relevant Access in Low Middle Income Countries

Psycho-Oncology in Low Middle Income Countries: Importance and Principal Components for Its Development

Dr. Henry is an Associate Professor in the Gerald Bronfman Department of Oncology. She is a FRQS Clinician-Scientist and a psychologist in the Department of Psychology and in the Louise-Granofsky Psychosocial Oncology Program of the Segal Cancer Centre at the Jewish General Hospital. Her research program aims to better conceptualize early determinants of mental health in oncology, leading to the development and testing of interventions to improve the quality of life of cancer patients. Her work combines translational research with a major focus on advanced cancer and head and neck oncology. She developed the FACT/MBIS McGill Body Image Concern Scale – Head and Neck, part of the internationally known FACT Measurement System. She is Co-Director of the FRQS-funded Quebec Research Group in Palliative and End-of-Life Care (RQSPAL) Axis I on optimizing quality of life, a group comprising of over 200 researchers and students across the province of Quebec. As part of this research network and in collaboration with the Center for Research and Intervention on Suicide, Ethical Issues and End of Life Practices, she is heading a Pan-Canadian initiative to improve clinical and research capacity to address suffering in patients requesting Medical Aid in Dying. Dr. Henry has received funding from the Canadian Institute for Health Research, the Fonds de recherche Sante - Quebec, Genzyme and Roche. She is a board member of the International Psycho-Oncology Society (IPOS). Her international work with IPOS and the World Health Organization involves chairing Training Academies designed to build capacity for psycho-oncology in Africa and more broadly for low-middle-income countries.

Challenges of psychosocial care in cancer patients during the pandemic in Perú. Access, adaptation and cultural perspective

Roxana Aguilar Velarde, President of ANPPE (National association of psycho-oncology of Peru). Master's Degree in Mental Health in Populations (UPCH). Degree in Psychology (UPSMP). Diploma in Psychoneuroimmunology (UPRP). International Diploma in Evaluation of the quality of adult education (Crefal-Unesco. Mexico). Training courses in psycho-oncology, neuroscience, bio, and neurofeedback. She currently works as a psychotherapist, as a consultant for international cooperation agencies and as a social researcher in public and private development projects and programs. Publications on public health issues. IPOS Member. Member of the International Academy of Proportional Social Cybernetics.

Role of cultural factors in psychosocial care of cancer patients and their caregivers

Dr. Santosh Kumar Chaturvedi. MD, FRCPsych., Consultant Psychiatrist Leicestershire Partnership NHS Trust, Leicester, UK. Former Dean, Behavioural Sciences, & Senior Professor of Psychiatry, National Institute of Mental Health & Neurosciences, Bangalore 560 029, India. More than 120 publications on Psychosocial oncology, end of life care, spirituality & palliative care in different International and National journals, & Books. Edited and published five books on the subject, including one on Communication skills in Palliative Care, published by VHAI and latest one on Clinical Psycho Oncology: Indian Perspectives and Research, 2021. Overall, more than 620 scientific publications.

Local is Global: connecting psycho-oncology

Christian Ntizimira, MD, MSc